```
=> d his

     (FILE 'HOME' ENTERED AT 09:38:46 ON 19 DEC 2007)

     FILE 'CAPLUS' ENTERED AT 09:39:08 ON 19 DEC 2007
                E US2006-591986/APPS
L1              1 S E3

     FILE 'REGISTRY' ENTERED AT 09:40:09 ON 19 DEC 2007

     FILE 'CAPLUS' ENTERED AT 09:40:19 ON 19 DEC 2007
L2              TRA L1 1- RN :       140 TERMS

     FILE 'REGISTRY' ENTERED AT 09:40:20 ON 19 DEC 2007
L3            140 SEA L2
                E  ACETAMIDE, N-[4-[2-[4-[2-[(AMINOIMINOMETHYL)AMINO]ETHYL]PHEN
                E  ACETAMIDE, N-[4-[2-[4-[2-[(AMINOIMINOMETHYL)AMINO]ETHYL]PHEN

     FILE 'REGISTRY' ENTERED AT 09:46:57 ON 19 DEC 2007
L4              STR 737826-48-1
L5              0 S L4 FAM SAM
                E  ACETAMIDE, N-[4-[2-[4-[2-[(AMINOIMINOMETHYL)AMINO]ETHYL]PHEN
                E  N-[4-[2-[4-[2-[(AMINOIMINOMETHYL)AMINO]ETHYL]PHENYL]ETHYL]-2
                E  737826-48-1/RN
L6              1 S E3

     FILE 'CAPLUS, USPATFULL, USPATOLD, USPAT2' ENTERED AT 09:50:10 ON 19 DEC
     2007
L7              9 S L6
L8              2 S L7 AND ( POLYOL OR SUGAR OR (SUGAR ALCOHOL) OR (BORIC ACID))
```

L1 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1042064 CAPLUS
DOCUMENT NUMBER: 143:332555
TITLE: Aqueous composition comprising thiazole derivative
INVENTOR(S): Ueno, Ryuji; Hirata, Ryu; Harada, Yasuhiro
PATENT ASSIGNEE(S): R-Tech Ueno, Ltd., Japan
SOURCE: PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
WO 2005089755	A1	20050929	WO 2005-JP5607		20050318	
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW						
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG						
CA 2558135	A1	20050929	CA 2005-2558135		20050318	
EP 1737450	A1	20070103	EP 2005-721534		20050318	
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR						
CN 1933833	A	20070321	CN 2005-80008447		20050318	
JP 2007529413	T	20071025	JP 2006-529411		20050318	
US 2007208068	A1	20070906	US 2006-591986		20060907	<--
PRIORITY APPLN. INFO.:			US 2004-553956P	P	20040318	
			WO 2005-JP5607	W	20050318	

OTHER SOURCE(S): MARPAT 143:332555
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 29 OF 140 REGISTRY COPYRIGHT 2007 ACS on STN
RN 737826-48-1 REGISTRY
ED Entered STN: 02 Sep 2004
CN Acetamide, N-[4-[2-[4-[2-[(aminoiminomethyl)amino]ethyl]phenyl]ethyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)
MF C16 H21 N5 O S . Cl H
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
CRN (737827-47-3)



● HCl

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L6 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN
RN 737826-48-1 REGISTRY
ED Entered STN: 02 Sep 2004
CN Acetamide, N-[4-[2-[4-[2-[(aminoiminomethyl)amino]ethyl]phenyl]ethyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)
MF C16 H21 N5 O S . Cl H
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
CRN (737827-47-3)



● HCl

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L7 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1042064 CAPLUS
DOCUMENT NUMBER: 143:332555
TITLE: Aqueous composition comprising thiazole derivative
INVENTOR(S): Ueno, Ryuji; Hirata, Ryu; Harada, Yasuhiro
PATENT ASSIGNEE(S): R-Tech Ueno, Ltd., Japan
SOURCE: PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005089755	A1	20050929	WO 2005-JP5607		20050318
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2558135	A1	20050929	CA 2005-2558135		20050318
EP 1737450	A1	20070103	EP 2005-721534		20050318
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR					
CN 1933833	A	20070321	CN 2005-80008447		20050318
JP 2007529413	T	20071025	JP 2006-529411		20050318
US 2007208068	A1	20070906	US 2006-591986		20060907
PRIORITY APPLN. INFO.:			US 2004-553956P	P	20040318
			WO 2005-JP5607	W	20050318

OTHER SOURCE(S): MARPAT 143:332555
AB The present invention provides an aqueous composition comprising a thiazole derivative
or a pharmaceutically acceptable salt thereof, and an additive selected from the group consisting of polyol, sugar, sugar alc., boric acid or its salt, and water. The aqueous composition is very stable and can be stored for a
long time. For example, a 0.3% aqueous solution of N-[4-[2-[4-[[amino(imino)methyl]amino]phenyl]ethyl]-5-[4-(methylsulfonyl)benzyl]-1,3-thiazol-2-yl]acetamide (I) (pH 6) was prepared using HCl acid and an additive selected from glycerin 2.5%, mannitol 4.7%, or boric acid 1.68%. The solution was stored at 40° in the low-d. polyethylene container. The concentration of the thiazole compound I after 1 mo, 3 mo, and 6 mo was 105.4,
110.6 and 112.3% of the original 100% concentration of I for glycerin, 103.7, 108.4 and 109.6% for mannitol, and 104.9, 106.2, and 108.2% for boric acid, resp.
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l7 ibib abs 2-

YOU HAVE REQUESTED DATA FROM 8 ANSWERS - CONTINUE? Y/(N):y

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:857384 CAPLUS
DOCUMENT NUMBER: 141:350160
TITLE: treatment of vascular hyperpermeable disease using acylaminothiazoles and related compounds as vascular adhesion protein-1 (VAP-1) inhibitors.
INVENTOR(S): Ueno, Ryuji; Nagashima, Akira; Inoue, Takayuki; Ohkubo, Mitsuru; Yoshihara, Kousei
PATENT ASSIGNEE(S): Sucampo Ag, Switz.; Fujisawa Pharmaceutical Co., Ltd.
SOURCE: PCT Int. Appl., 269 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004087138	A1	20041014	WO 2004-JP4596		20040331
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2520957	A1	20041014	CA 2004-2520957		20040331
EP 1608365	A1	20051228	EP 2004-724735		20040331
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK					
CN 1794988	A	20060628	CN 2004-80009070		20040331
JP 2006522110	T	20060928	JP 2006-507702		20040331
US 2006229346	A1	20061012	US 2005-550414		20050923
PRIORITY APPLN. INFO.:			US 2003-458370P	P	20030331
			WO 2004-JP4596	W	20040331

OTHER SOURCE(S): MARPAT 141:350160
GI



I

AB A method for treating a vascular hyperpermeable disease (except macular edema), comprises administration of a vascular adhesion protein-1 (VAP-1) inhibitor in an amount sufficient to treat said patient for said disease. Thus, N-[4-[2-(4-aminophenyl)ethyl]-1,3-thiazol-2-yl]acetamide (preparation given) was refluxed with HCl and cyanamide in EtOH for 26 h to give title compound (I). I inhibited human plasma VAP-1 (SSAO) with IC50 = 0.15 μM.
REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:648516 CAPLUS
DOCUMENT NUMBER: 141:190785
TITLE: Preparation of thiazole derivatives as VAP-1 inhibitors for treatment of macular edema and other VAP-1 associated diseases
INVENTOR(S): Inoue, Takayuki; Tojo, Takashi; Morita, Masataka; Ohkubo, Mitsuru; Yoshihara, Kousei; Nagashima, Akira
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 268 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004067521	A1	20040812	WO 2004-JP708		20040127
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI					
CA 2514573	A1	20040812	CA 2004-2514573		20040127
US 2004259923	A1	20041223	US 2004-764529		20040127
US 7125901	B2	20061024			
EP 1587800	A1	20051026	EP 2004-705519		20040127
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
CN 1761655	A	20060419	CN 2004-80007682		20040127
JP 2006516611	T	20060706	JP 2006-502657		20040127
US 2006128770	A1	20060615	US 2006-345492		20060202
US 2006276521	A1	20061207	US 2006-505321		20060817
PRIORITY APPLN. INFO.:			US 2003-442509P	P	20030127
			US 2003-458369P	P	20030331
			US 2003-517377P	P	20031106
			US 2004-764529	A3	20040127
			WO 2004-JP708	W	20040127

OTHER SOURCE(S): MARPAT 141:190785
GI



II

AB Title compds. of formula R1NHXYZ [I; wherein R1 = acyl; X = a bivalent (un)substituted thiazole; Y = a bond, alkylene, alkenylene, COHN; Z = 2-aminobenzimidazolyl, C6H4-R2; R2 = ABDE; A = a bond, alkylene, NH, SO2; B = a bond , alkylene, CO, O; D = a bond, alkylene, NH, CH2NH; E = (un)protected amino, N=CH2, dihydrothiazol-2-yl, dihydroimidazol-2-yl, C(=NH)R3; R3 = H, alkyl(thio), NHR4; R4 = H, NH2, alkyl; and pharmaceutically acceptable salts thereof] were prepared as vascular adhesion protein-1 (VAP-1) inhibitors. For example, cycloaddn. of 3-chloro-2-oxopropyl acetate and thiourea in EtOH gave (2-amino-1,3-thiazol-4-yl)methyl acetate•HCl, which was amidated with acetyl chloride using pyridine in CH2Cl2. Deprotection of [2-(acetylamino)thiazol-4-yl]methyl acetate using K2CO3 in MeOH, followed by reaction of the resulting alc. with MnO2 in MeOH/CHCl3 provided N-(4-formylthiazol-2-yl)acetamide. Coupling of the aldehyde with 1-(bromomethyl)-4-nitrobenzene in the presence of PPh3 and t-BuOH in DMF gave N-[4-[(Z)-2-(4-nitrophenyl)ethenyl]thiazol-2-yl]acetamide, which was reduced to the amine with Pd/C in MeOH/THF/AcOH. Finally, coupling of the amine with cyanamide in the presence of HCl in EtOH/EtOAc afforded II. The latter inhibited VAP-1 enzyme (SSAO) activity in both human and rat plasma (IC50 = 0.15 μM and 0.012 μM, resp.), but not the enzyme activities of other amine oxidases (IC50 >100μM), such as human platelet monoamine oxidase (MAO) and cloned diamine oxidase (DAO, histaminase). Treatment of diabetic rats daily with II (10 mg/kg/ s.c. u.i.d.) improved their ocular permeability in comparison with the diabetic control group (vitreous/plasma ratio of fluorescein concns. = 5.39 ± 0.73 x10-3 and 8.93 ± 1.14 x10-3, resp.). Thus, I and their pharmaceutical compns. are useful for preventing or treating VAP-1 associated diseases, especially macular edema (no data).

L7 ANSWER 4 OF 9 USPATFULL on STN

ACCESSION NUMBER:	2007:237692 USPATFULL			
TITLE:	Aqueous Composition Comprising Thiazole Derivative			
INVENTOR(S):	Ueno, Ryuji, Montgomery, MD, UNITED STATES Hirata, Ryu, Hyogo-ken, JAPAN Harada, Yasuhiro, Hyogo-ken, JAPAN			
PATENT ASSIGNEE(S):	R-TECH UENO, LTD. & Astellas Pharma Inc. (U.S. corporation)			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2007208068	A1	20070906	
APPLICATION INFO.:	US 2005-591986	A1	20050318	(10)
	WO 2005-JP5607		20050318	
			20060907	PCT 371 date
	NUMBER		DATE	
PRIORITY INFORMATION:	US 2004-553956P		20040318	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SUGHRUE MION, PLLC, 2100 PENNSYLVANIA AVENUE, N.W., SUITE 800, WASHINGTON, DC, 20037, US
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
LINE COUNT: 675
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides an aqueous composition comprising a thiazole derivative of the formula (I): R.sup.1--NH--X--Y-Z (I) wherein each symbol is as defined above, or a pharmaceutically acceptable salt thereof, and an additive selected from the group consisting of polyol, sugar, sugar alcohol, boric acid or its salt, and water. The aqueous composition is very stable and can be stored for a long time.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 5 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2006:322475 USPATFULL
TITLE: Thiazole derivatives
INVENTOR(S): Inoue, Takayuki, Osaka-shi, JAPAN
Tojo, Takashi, Osaka-shi, JAPAN
Morita, Masataka, Osaka-shi, JAPAN
Ohkubo, Mitsuru, Osaka-shi, JAPAN
Yoshihara, Kousei, Osaka-shi, JAPAN
Nagashima, Akira, Osaka-shi, JAPAN
PATENT ASSIGNEE(S): Astellas Pharma Inc., Chuo-ku, JAPAN, 103-8411 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006276521	A1	20061207
APPLICATION INFO.:	US 2006-505321	A1	20060817 (11)

RELATED APPLN. INFO.: Division of Ser. No. US 2004-764529, filed on 27 Jan 2004, GRANTED, Pat. No. US 7125901

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-442509P	20030127 (60)
	US 2003-458369P	20030331 (60)
	US 2003-517377P	20031106 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: C. IRVIN MCCLELLAND, OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C., 1940 DUKE STREET, ALEXANDRIA, VA, 22314, US
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1-23
LINE COUNT: 7571
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound of the formula (I): R.sup.1--NH--X--Y-Z (I) wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, a method for preventing or treating a VAP-1 associated disease, especially macular edema, which method includes administering an effective amount of the compound or a pharmaceutically acceptable salt thereof to a mammal, and the like.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 6 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2006:268652 USPATFULL
TITLE: Method for treating vascular hyperpermeable disease
INVENTOR(S): Ueno, Ryuji, 11025 Stanmore Drive, Potomac, Montgomery, MD, UNITED STATES 20854
Nagashima, Akira, Tokyo, JAPAN
Inoue, Takayuki, Tokyo, JAPAN
Ohkubo, Mitsuru, Tokyo, JAPAN
Yoshihara, Kousci, Tokyo, JAPAN
PATENT ASSIGNEE(S): Sucampo AG, Zug, SWITZERLAND, CH-6300 (non-U.S. corporation)
Astellas Pharma Inc., Tokyo, JAPAN, 103-8411 (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2006229346	A1	20061012	
APPLICATION INFO.:	US 2004-550414	A1	20040331	(10)
	WO 2004-JP4596		20040331	
			20050923	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-458370P	20030331 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C., 1940 DUKE STREET, ALEXANDRIA, VA, 22314, US
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 7470
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a method for treating a vascular hyperpermeable disease (except macular edema), which method comprises administering to a patient in need thereof a vascular adhesion protein-1 (VAP-1) inhibitor in an amount sufficient to treat said patient for said disease. The agents are 2-acylamino thiazole compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 7 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2006:152329 USPATFULL
TITLE: Thiazole derivatives
INVENTOR(S): Inoue, Takayuki, Osaka-shi, JAPAN
Tojo, Takashi, Osaka-shi, JAPAN
Morita, Masataka, Osaka-shi, JAPAN
Ohkubo, Mitsuru, Osaka-shi, JAPAN
Yoshihara, Kousei, Osaka-shi, JAPAN
Nagashima, Akira, Osaka-shi, JAPAN
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co. Ltd., Osaka, JAPAN (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2006128770	A1	20060615	
APPLICATION INFO.:	US 2006-345492	A1	20060202	(11)
RELATED APPLN. INFO.:	Division of Ser. No. US 2004-764529, filed on 27 Jan 2004, PENDING			

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-442509P	20030127 (60)
	US 2003-458369P	20030331 (60)
	US 2003-517377P	20031106 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C., 1940 DUKE STREET, ALEXANDRIA, VA, 22314, US
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
LINE COUNT: 7558
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A compound of the formula (I): R.sup.1--NH--X--Y-Z (I) wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, a method for preventing or treating a VAP-1 associated disease, especially macular edema, which method includes administering an effective amount of the compound or a pharmaceutically acceptable salt thereof to a mammal, and the like.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 8 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2004:328098 USPATFULL
TITLE: Thiazole derivatives
INVENTOR(S): Inoue, Takayuki, Osaka, JAPAN
Tojo, Takashi, Osaka, JAPAN
Morita, Masataka, Osaka, JAPAN
Ohkubo, Mitsuru, Osaka, JAPAN
Yoshihara, Kousei, Osaka, JAPAN
Nagashima, Akira, Osaka, JAPAN
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co. Ltd., Osaka, JAPAN, 541-8514 (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004259923	A1	20041223	
	US 7125901	B2	20061024	
APPLICATION INFO.:	US 2004-764529	A1	20040127	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-442509P	20030127 (60)
	US 2003-458369P	20030331 (60)
	US 2003-517377P	20031106 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C., 1940 DUKE STREET, ALEXANDRIA, VA, 22314
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
LINE COUNT: 7425
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A compound of the formula (I): R.sup.1--NH--X--Y-Z (I) wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, a method for preventing or

treating a VAP-1 associated disease, especially macular edema, which method includes administering an effective amount of the compound or a pharmaceutically acceptable salt thereof to a mammal, and the like.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 9 OF 9 USPAT2 on STN

ACCESSION NUMBER:	2004:328098 USPAT2		
TITLE:	Thiazole derivatives		
INVENTOR(S):	Inoue, Takayuki, Osaka, JAPAN Tojo, Takashi, Osaka, JAPAN Morita, Masataka, Osaka, JAPAN Ohkubo, Mitsuru, Osaka, JAPAN Yoshihara, Kousei, Osaka, JAPAN Nagashima, Akira, Osaka, JAPAN		
PATENT ASSIGNEE(S):	Astellas Pharma Inc., Tokyo, JAPAN (non-U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 7125901	B2	20061024
APPLICATION INFO.:	US 2004-764529		20040127 (10)
	NUMBER		DATE
PRIORITY INFORMATION:	US 2003-517377P		20031106 (60)
	US 2003-458369P		20030331 (60)
	US 2003-442509P		20030127 (60)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Solola, Taofiq		
LEGAL REPRESENTATIVE:	Oblon, Spivak, McClelland, Maier & Neustadt, P.C.		
NUMBER OF CLAIMS:	10		
EXEMPLARY CLAIM:	1		
LINE COUNT:	7514		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound of the formula (I): R.sup.1--NH--X--Y-Z (I) wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, a method for preventing or treating a VAP-1 associated disease, especially macular edema, which method includes administering an effective amount of the compound or a pharmaceutically acceptable salt thereof to a mammal, and the like.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Wednesday, December 19, 2007

Hide?	Set Name	Query	Hit Count
	DB=PGPB,USPT; THES=ASSIGNEE; PLUR=YES; OP=ADJ		
☐	L4	(us-20040067521-a1.did.)	1
☐	L3	((inoue.in. and morita.in.) and Thiazole.ti.)	5
☐	L2	(4780465.did.)	1
☐	L1	US-20040259923-A1.did.	1

END OF SEARCH HISTORY

Dec 19, 2007

12:41pm Searched for thiazole

12:36pm Searched for bivalent - Viewed 1 result

Bivalent - Wikipedia, the free encyclopedia - wikipedia.org

12:16pm Searched for alkenylene definition

12:16pm Searched for alkenylene - Viewed 1 result

Aryloxy-, arylthio-, heteroaryloxy-, heteroarylthio-alkenylen... - freepatentsonline.com

9:14am Searched for lower alkylene

9:14am Searched for lwer alkalene

8:56am Searched for acyl - Viewed 1 result

http://en.wikipedia.org/wiki/Acyl

8:55am Searched for thiazole - Viewed 1 result

Thiazole - Wikipedia, the free encyclopedia - wikipedia.org - See 1 more page